Bio-Rad Laboratories/$BIO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Bio-Rad Laboratories
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Ticker
$BIO
Sector
Primary listing
NYSE
Industry
Life Sciences Tools & Services
Headquarters
Employees
7,700
ISIN
US0905722072
Website
BIO Metrics
BasicAdvanced
$6.8B
-
-$77.10
1.12
-
Price and volume
Market cap
$6.8B
Beta
1.12
52-week high
$373.69
52-week low
$211.43
Average daily volume
406K
Financial strength
Current ratio
5.994
Quick ratio
4.143
Long term debt to equity
19.867
Total debt to equity
20.503
Interest coverage (TTM)
5.64%
Profitability
EBITDA (TTM)
426.8
Gross margin (TTM)
53.64%
Net profit margin (TTM)
-85.16%
Operating margin (TTM)
10.79%
Effective tax rate (TTM)
21.31%
Revenue per employee (TTM)
$330,000
Management effectiveness
Return on assets (TTM)
1.55%
Return on equity (TTM)
-27.51%
Valuation
Price to revenue (TTM)
2.779
Price to book
1.04
Price to tangible book (TTM)
1.16
Price to free cash flow (TTM)
21.262
Free cash flow yield (TTM)
4.70%
Free cash flow per share (TTM)
1,183.12%
Growth
Revenue change (TTM)
-2.46%
Earnings per share change (TTM)
591.77%
3-year revenue growth (CAGR)
-4.26%
10-year revenue growth (CAGR)
1.74%
3-year earnings per share growth (CAGR)
193.89%
10-year earnings per share growth (CAGR)
36.52%
What the Analysts think about BIO
Analyst ratings (Buy, Hold, Sell) for Bio-Rad Laboratories stock.
Bulls say / Bears say
Bio-Rad Laboratories' Clinical Diagnostics segment demonstrated resilience, with net sales increasing by 5.3% in Q4 2023 compared to the same period in 2022, driven by strong demand for diabetes and quality control products. (biospace.com)
The company has been actively expanding its product portfolio, including the introduction of the ddPCR Microsatellite Instability (MSI) Kit and supporting software for oncology applications, positioning itself in the growing field of cancer diagnostics. (stocktitan.net)
Bio-Rad's strategic acquisition of digital PCR developer Stilla Technologies is expected to enhance its capabilities in digital PCR, supporting a diverse range of research and clinical diagnostic applications. (biospace.com)
The Life Science segment experienced a significant decline, with net sales decreasing by 19.1% in Q4 2023 compared to the same period in 2022, primarily due to lower sales of ddPCR, qPCR, and Western blotting products. (biospace.com)
Bio-Rad Laboratories cut its annual revenue growth forecast in August 2024, expecting a decline of 2.5% to 4% for the year, attributed to weak demand for clinical diagnostics products from biotech clients. (reuters.com)
The company reported a decrease in total net sales for Q1 2025, with revenue dropping to $585.4 million from $610.8 million in the same period the previous year, reflecting ongoing challenges in the academic research market, particularly in the Americas. (biospace.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jul 2025.
BIO Financial Performance
Revenues and expenses
BIO Earnings Performance
Company profitability
BIO News
AllArticlesVideos
Bio-Rad's Management to Host Investor Meetings During Jefferies Global Healthcare Conference
Business Wire·1 month ago
Bio-Rad's Management to Participate in Fireside Chat During 2025 RBC Capital Markets Global Healthcare Conference
Business Wire·2 months ago
Bio-Rad Reports First-Quarter 2025 Financial Results
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Bio-Rad Laboratories stock?
Bio-Rad Laboratories (BIO) has a market cap of $6.8B as of July 08, 2025.
What is the P/E ratio for Bio-Rad Laboratories stock?
The price to earnings (P/E) ratio for Bio-Rad Laboratories (BIO) stock is 0 as of July 08, 2025.
Does Bio-Rad Laboratories stock pay dividends?
No, Bio-Rad Laboratories (BIO) stock does not pay dividends to its shareholders as of July 08, 2025.
When is the next Bio-Rad Laboratories dividend payment date?
Bio-Rad Laboratories (BIO) stock does not pay dividends to its shareholders.
What is the beta indicator for Bio-Rad Laboratories?
Bio-Rad Laboratories (BIO) has a beta rating of 1.12. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.